V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160013743 | 160006698 | 1.75 | 53.6 | Palliative (P) | 2016-11-23 | 2016-11-23 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101042294 |
| 160013745 | 160006699 | 1.73 | 75.6 | Neo-adjuvant (N) | 2018-02-28 | 2018-03-01 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 100021983 |
| 160013747 | 160006700 | 1.74 | 100.2 | Palliative (P) | 2017-10-06 | 2017-11-03 | DOXORUBICIN | 02 | N | DOXORUBICIN | 100567257 |
| 160013749 | 160006701 | 1.8 | 55.9 | null | 2018-04-21 | 2018-04-21 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101737859 |
| 160013750 | 160006702 | 1.72 | 87.4 | Palliative (P) | 2016-07-05 | 2016-07-09 | BEVACIZUMAB + CARBO + PACLITAXEL | N | N | TRIAL | 100442061 |
| 160013752 | 160006703 | 1.65 | 44.4 | Curative (C) | 2019-10-03 | 2019-10-03 | Dactinomycin + Vincristine | N | N | DOXORUBICIN + IFOSFAMIDE | 100067517 |
| 160013754 | 160006704 | 1.59 | 90 | Palliative (P) | 2017-04-28 | 2017-04-29 | CHOP R - 21 days | 02 | N | CISPLATIN + PEMETREXED | 100649601 |
| 160013756 | 160006705 | null | 82 | Curative (C) | 2019-03-07 | 2019-03-11 | Liposomal Doxorubicin (Caelyx) | 02 | null | STS RHABDO RMS 2005 VIN CYCLO | 100205619 |
| 160013762 | 160006707 | 1.61 | 92 | Palliative (P) | 2018-06-02 | 2019-03-18 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101718561 |
| 160013765 | 160006708 | 1.75 | 71.15 | Neo-adjuvant (N) | 2017-12-26 | 2018-01-07 | Doxorubicin + Ifosfamide | N | N | VIDE | 100850737 |
| 160013767 | 160006709 | 1.73 | 115 | null | 2018-10-03 | 2018-10-03 | DACARBAZINE + DOXORUBICIN | 02 | null | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 100169701 |
| 160013768 | 160006710 | 1.52 | null | Palliative (P) | 2019-10-19 | 2019-10-21 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101493220 |
| 160013769 | 160006711 | 1.82 | 5.7 | Adjuvant (A) | 2018-02-12 | 2018-02-12 | Trial Unspecified | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100521430 |
| 160013770 | 160006712 | 1.55 | 74.5 | Neo-adjuvant (N) | 2016-03-07 | 2016-03-14 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100707494 |
| 160013771 | 160006713 | 1.7 | 81 | Palliative (P) | 2017-12-27 | 2017-12-27 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101474557 |
| 160013774 | 160006714 | 165 | 81.5 | Curative (C) | null | 2016-10-20 | Doxorubicin + Olaratumab | 02 | N | ETOP 13-18 BEAT-MESO TRIAL | 101792186 |
| 160013775 | 160006715 | 1.67 | 63.8 | Palliative (P) | 2019-07-30 | 2019-08-24 | Docetaxel + Gemcitabine (prior RT) | 02 | N | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 101110679 |
| 160013776 | 160006716 | 1.58 | 77.2 | null | 2018-04-23 | 2018-05-06 | Carboplatin AUC 6 - 10 | 02 | null | CARBOPLATIN | 100080136 |
| 160013777 | 160006717 | 1.82 | 98.9 | null | 2017-04-30 | 2017-05-04 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101359241 |
| 160013778 | 160006718 | 1.6 | 80.5 | Curative (C) | 2017-12-16 | 2017-12-16 | Carboplatin AUC 2 - 5 | N | N | CARBOPLATIN | 101058033 |
| 160013780 | 160006720 | 1.78 | 75.2 | Palliative (P) | 2018-05-18 | 2018-05-26 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100980541 |
| 160013782 | 160006722 | null | 65.1 | Palliative (P) | 2018-03-12 | 2018-03-29 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100150842 |
| 160013783 | 160006723 | 1.56 | 92.2 | Palliative (P) | 2017-06-06 | 2017-06-21 | null | N | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 101737644 |
| 160013784 | 160006724 | 1.83 | 80.8 | Curative (C) | 2019-08-19 | 2019-08-19 | Doxorubicin + Ifosfamide | 01 | N | CISPLATIN + PEMETREXED | 101234502 |
| 160013785 | 160006725 | 1.77 | 71.9 | Neo-adjuvant (N) | 2019-11-09 | 2019-11-21 | Doxorubicin + Ifosfamide | 01 | N | DOXORUBICIN + IFOSFAMIDE | 100750615 |
| 160013790 | 160006727 | 1.7 | 79.3 | Neo-adjuvant (N) | 2017-01-26 | 2017-02-15 | Ipilimumab | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100715212 |
| 160013791 | 160006728 | 1.8 | null | Palliative (P) | 2020-07-19 | 2020-07-20 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101326308 |
| 160013792 | 160006729 | 1.79 | 57.6 | Curative (C) | 2018-01-15 | 2018-01-15 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101553245 |
| 160013793 | 160006730 | 0 | 4.1 | Palliative (P) | 2018-10-15 | 2018-10-31 | Sunitinib | 02 | N | DOXORUBICIN | 100695175 |
| 160013795 | 160006731 | 0 | 101 | null | 2019-08-06 | 2019-08-06 | EW EuroEwing 2012 Arm A VIDE | 02 | null | DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE | 100461406 |
| 160013796 | 160006732 | 1.87 | 19.1 | Curative (C) | 2018-07-17 | 2018-07-17 | Carboplatin + Paclitaxel (3 weekly) | null | N | DOXORUBICIN | 100413282 |
| 160013797 | 160006733 | 1.82 | 80.4 | Neo-adjuvant (N) | 2020-03-12 | 2020-03-12 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101207385 |
| 160013798 | 160006734 | 1.7 | 55 | null | 2014-04-18 | 2014-04-18 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100313486 |
| 160013799 | 160006735 | 1.77 | 112 | Curative (C) | null | 2017-10-18 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101450659 |
| 160013801 | 160006736 | 1.64 | 70.6 | Palliative (P) | 2019-01-18 | 2019-01-27 | Doxorubicin + Ifosfamide | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100509946 |
| 160013803 | 160006737 | null | 66 | Palliative (P) | 2018-11-03 | 2018-11-27 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100535463 |
| 160013805 | 160006738 | 1.84 | 50 | Palliative (P) | 2018-06-07 | 2018-06-13 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100328430 |
| 160013806 | 160006739 | 1.8 | 85.3 | null | 2019-12-25 | 2020-01-08 | Trial Unspecified | 02 | N | TRIAL UNSPECIFIED | 100559166 |
| 160013808 | 160006740 | 1.65 | 119 | Neo-adjuvant (N) | null | 2018-03-02 | Bevacizumab+Carbo+Pacliaxel | N | N | DOXORUBICIN + OLARATUMAB | 101594650 |
| 160013809 | 160006741 | 1.87 | 85 | Neo-adjuvant (N) | 2019-03-11 | 2019-03-24 | Liposomal Doxorubicin (20mg/m2) | N | N | LIPOSOMAL DAUNORUBICIN | 100071353 |
| 160013811 | 160006742 | 1.75 | 88 | Palliative (P) | 2017-11-06 | 2017-11-25 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 02 | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 100289236 |
| 160013812 | 160006743 | 1.14 | 86 | Palliative (P) | 2021-09-01 | 2021-09-03 | Doxorubicin + Ifosfamide | 02 | null | LIPOSOMAL DOXORUBICIN | 100734467 |
| 160013814 | 160006744 | 1.68 | 100 | Palliative (P) | 2017-04-05 | 2017-04-22 | Doxorubicin + Olaratumab | null | Y | DOXORUBICIN + OLARATUMAB | 101481740 |
| 160013817 | 160006745 | 1.75 | 88 | Palliative (P) | 2019-09-15 | 2019-09-30 | Cisplatin + Doxorubicin | N | N | HYDROXYCARBAMIDE | 100398368 |
| 160013818 | 160006746 | 1.85 | 60 | Adjuvant (A) | 2017-12-31 | 2018-01-01 | STS Rhabdomyosarco RMS 2005 IVADoVV | N | N | DOXORUBICIN | 100331245 |
| 160013819 | 160006747 | 1.61 | 51.2 | Palliative (P) | 2021-05-12 | 2021-06-15 | Temozolomide 150mg/m2 | Y | N | DOXORUBICIN + IFOSFAMIDE | 100051360 |
| 160013823 | 160006748 | 1.83 | 82.6 | 03 | 2016-05-19 | 2016-05-19 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100545757 |
| 160013824 | 160006749 | 1.52 | 94.8 | null | 2017-04-26 | 2017-05-04 | Trial Unspecified | 99 | N | CISPLATIN + PEMETREXED | 100006032 |
| 160013826 | 160006751 | 1.54 | 78 | Palliative (P) | 2019-09-22 | 2019-09-23 | Carboplatin + Paclitaxel (3 weekly) | N | N | CARBOPLATIN + PACLITAXEL | 100112479 |
| 160013828 | 160006752 | 1.6 | 58.5 | Palliative (P) | 2019-06-13 | 2019-06-27 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100122744 |